期刊
NPJ VACCINES
卷 6, 期 1, 页码 -出版社
NATURE PORTFOLIO
DOI: 10.1038/s41541-021-00370-z
关键词
-
资金
- KTP-NUCMI
- National University Health System
- Career Development Award from the Agency for Science, Technology and Research, Singapore
- National Medical Research Council Open Fund-Young Investigator Research Grant from the Ministry of Health, Singapore [MOH-000545-00]
- SARS-CoV-2 antibody initiative [R-571-000-081-213]
- Reimagine research fund [R-571-001-093-114]
Lactating mothers who received the BNT162b2 vaccine secreted SARS-CoV-2-specific antibodies into milk, providing protective immunity. Minimal transfer of vaccine mRNA was detected, and no adverse effects were reported in recipients.
Lactating women can produce protective antibodies in their milk after vaccination, which has informed antenatal vaccination programs for diseases such as influenza and pertussis. However, whether SARS-CoV-2-specific antibodies are produced in human milk as a result of COVID-19 vaccination is still unclear. In this study, we show that lactating mothers who received the BNT162b2 vaccine secreted SARS-CoV-2-specific IgA and IgG antibodies into milk, with the most significant increase at 3-7 days post-dose 2. Virus-specific IgG titers were stable out to 4-6 weeks after dose 2. In contrast, SARS-CoV-2-specific IgA levels showed substantial decay. Vaccine mRNA was detected in few milk samples (maximum of 2 ng/ml), indicative of minimal transfer. Additionally, infants who consumed post-vaccination human milk had no reported adverse effects up to 28 days post-ingestion. Our results define the safety and efficacy profiles of the vaccine in this demographic and provide initial evidence for protective immunity conferred by milk-borne SARS-CoV-2-specific antibodies. Taken together, our study supports recommendations for uninterrupted breastfeeding subsequent to mRNA vaccination against COVID-19.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据